Merck & Co Inc
(LTS:0QAH)
$
131.3
0 (0%)
Market Cap: 249.37 Bil
Enterprise Value: 272.91 Bil
PE Ratio: 20.67
PB Ratio: 5.61
GF Score: 81/100 Merck & Co Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 02:30PM GMT
Release Date Price:
$73.4
(-3.51%)
David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst
So I will sit down in just a moment to join Merck. But it's very much my pleasure to welcome both Ken Frazier and Roger Perlmutter. I need to start off with the disclaimers. We need to refer you to the disclaimers at www.morganstanley.com/researchdisclosures.
And as you know, Ken serves as President and CEO of Merck. He originally joined the company in 1992 and was named CEO of Merck in 2011. And Roger has served as Executive Vice President and President of Merck Research Labs since 2013. He originally joined Merck in 1997 and then served as Head of R&D at Amgen from 2001 to 2012 before returning to Merck. So we're fortunate to have both of you with us today. Thanks for being here.
Questions & Answers
David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst
Maybe, Ken
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot